Search Results for: geron

The recipe for success for stem cell biotechs such as Geron, ACT, and ViaCyte: 3 key ingredients

What will we define as a success for any given stem cell biotech? In academia, even if we do pre-clinical, translational kind of biomedical sciences, we still do not often think about what it takes to succeed in industry. Even if we very much want our research to make a difference for patients, do we …

The recipe for success for stem cell biotechs such as Geron, ACT, and ViaCyte: 3 key ingredients Read More »

Advanced Cell Technology and Geron: allies or competitors?

Geron-300x2212

Two companies, Advanced Cell Technology (ACT) and Geron, both HQ’d here in California, have FDA-approved early stage clinical trials in the works. Geron’s trial has already started and reportedly now has enrolled at least two patients. The trial is of course for the safety of Geron’s GRNOPC1 oligodendrocyte product made from human ES cells for …

Advanced Cell Technology and Geron: allies or competitors? Read More »

Stem Cell Clinical Trials Part I: Geron VP Lebkoswki speaking today in Seattle

This morning there was a fantastic session here at the ASGCT meeting in Seattle on Clinical Trials on Stem Cells. One of the speakers was Geron VP, Jane Lebkoswki, PhD: Development of Human Embryonic Stem Cell-Based Therapies for Treatment of Human Degenerative Diseases. The talk was focused on OPC1 for the treatment of spinal cord …

Stem Cell Clinical Trials Part I: Geron VP Lebkoswki speaking today in Seattle Read More »

CIRM funds $25 million for Geron trial, $38 million for basic biology

Geron-300x2212

CIRM announced two sets of awards today that both should make major impact including its first clinical trial via Geron and $38 million for 27 basic biology studies. First Clinical Trial. Today CIRM awarded $25 million to support Geron’s FDA-approved clinical trial for spinal cord injury. This is CIRM’s first award to a for-profit company …

CIRM funds $25 million for Geron trial, $38 million for basic biology Read More »

Myth of Perfect Stem Cell: meaning for ACT, Geron and field

in-science-we-trust

  There are a lot of myths in the stem cell field, some even embraced by some stem cell scientists such as the notion that teratoma are always benign. But when we start talking about translating stem cell technology into the clinic, to the bedside, it is especially important to cast aside our myths, no …

Myth of Perfect Stem Cell: meaning for ACT, Geron and field Read More »

Stem cell biotech updates: Geron, ACT, Neuralstem, Pfizer

What’s going on these days with biotech companies working on stem cell-based products? Geron’s and Advanced Cell Technology (ACT)’s FDA-approved trials presumably continue. As expected, no news yet. It’s too soon. Two important questions regarding both these companies are (1) did they apply for CIRM funding and (2) if so, how did the review process …

Stem cell biotech updates: Geron, ACT, Neuralstem, Pfizer Read More »

Autologous or Allogeneic: a stem cell question (guest post from Jeanne Loring)

stem-cells-and-development-parkinsons-disease

By Jeanne Loring What can you do with cells that live forever and can make every cell type in the body?  The answer is: remarkable things, as new reports of clinical trials using cell types derived from pluripotent stem cells indicate. Pluripotent stem cells are either derived from embryos donated from IVF procedures (human embryonic …

Autologous or Allogeneic: a stem cell question (guest post from Jeanne Loring) Read More »

Stem cells for the flu? Pondering PR email, frailty data from Longeveron

Tompkins-Figure-2A

Stem cells for flu? For me, that idea is new. Some months back there was buzz about the stem cell biotech Longeveron related to its report on early trial data on testing infusions of mesenchymal stem cells for frailty in the aged. Frailty that pops up in some aging folks can manifest in a variety …

Stem cells for the flu? Pondering PR email, frailty data from Longeveron Read More »

Asterias interview: stem cell spinal cord injury trials advance

Asterias

Recently I had the opportunity to talk with the leadership of Asterias, a California biotech doing exciting clinical research using stem cells as the basis for treatment of spinal cord injury. The interview covers the past (Geron patients), present, and future. I spoke with Asterias President and CEO Stephen Cartt and CMO Edward Wirth. How …

Asterias interview: stem cell spinal cord injury trials advance Read More »

Hateful politics infiltrate human genome editing debate in France

Stop-Baby-GMO-Campaign-e1466871220436

By Elliot Hosman Summary.  A campaign calling for a moratorium on using CRISPR in human embryos was launched by a prominent French organization fighting for narrow understandings of life and family. A recent campaign calling for a ban on “transgenic” human embryos was launched by one of France’s most prominent organizations fighting for “science”-backed “one-man-one-woman” …

Hateful politics infiltrate human genome editing debate in France Read More »